Pembrolizumab + Epacadostat vs Pembrolizumab + Placebo in Recurrent or Progressive Metastatic Urothelial Carcinoma
Status:
Completed
Trial end date:
2020-07-23
Target enrollment:
Participant gender:
Summary
The purpose of this study was to evaluate the efficacy and safety of pembrolizumab +
epacadostat vs pembrolizumab + placebo as a treatment for recurrent or progressive metastatic
urothelial carcinoma in patients who have failed a first-line platinum-containing
chemotherapy regimen for advanced/metastatic disease.